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Introduction: Optimal preoperative treatment of stage IIB/III NSCLC 
is yet unknown and a subject of controversy. Induction chemotherapy 
(CT) yields a pathologic response (pCR) rate ranging from 8 to 19% 
and a mediastinal down-staging rate ranging from 45 to 60%. Ac-
cording to results of the INT0139 trial (Albain KS et al, Proc ASCO 
2005, abstr#7014) and recent published data (Kwong KF et al, JTCS 
2005;129:1250-7) induction chemo-radiotherapy (CRT) seems superior 
in terms of pCR (18-40.5%). Our goal is to conﬁrm pCR and analyse 
survival after CRT in our community-based treatment center. 
Patients et method: Patients (pts) were selected in a multidisciplinary 
committee according to functional and resecability criteria. Induc-
tion treatment comprised 45 Gy RT delivered to primary tumor and 
pathologic hilar and/or mediastinal nodes on CT-can (CTV) with an 
extra-margin of 1 to 1.5 cm (PTV). A 5-ﬁeld technique was used for all 
patients with 8-25 MV photons. Concurrent CT regimen was CDDP 20 
mg/m2 d1-d5 and Etoposide 50 mg/m2 d1-d5 (PE), d1-5 d29-33; 3 to 
4 weeks after CRT completion, operability was re-assessed according 
to PS and a CT-scan. Surgery was performed 1 to 2 weeks later in pts 
deemed resectable. Inoperable pts were referred for a 20 Gy boost ± 1 
extra-cycle of PE.
Results: from 1996 to 2005, 107 pts (91H/16F, median age: 59 yrs. 
[31-81], OMS 0-1: 94.4%) were initially selected and received CRT 
(stage IIB(Pancoast) 18, IIIA 58 and IIIB 31, SCC 48%, Adeno.44%, 
Large c.14%). 2 pts stopped treatment prematurely (sudden death 1, 
refusal 1), 100 pts received 45 Gy and 2 cycles de PE concurrently 
(fatigue 3, renal failure 1, unknown reason 1), 72 pts had a thora-
cotomy after preop evaluation (pneumonectomy 21, lobectomy 45, 
bi-lobectomy 5, exploratory only 1). During the 3-months postop time, 
5 pts (6.9%) died, 4 after pneumonectomy (R 3, L 1). The analysis of 
tumoral samples showed a pCR (or microscopic residual foci) rate of 
39.5% in 71 cTany Nany pts and a sterilized mediastinal nodes rate of 
60.9% in 46 cTanyN2 pts. Median (med) follow-up time of survivors 
was 36.8 months (mo.), 2yrs. and 3yrs.-OS was 55 et 40% respec-
tively (med=26.7 mo.) for all the ITT population (n=107), 62 et 51% 
(med=36,5 mo.) for 71 resected, 41 and 16% for the 36 non-resected 
pts (med=19,1 mo.). On multivariate analysis, surgical resection and 
tumoral necrosis > 50% (or pCR) were the most pertinent predic-
tive factors of the risk of death (HR=.50 and .48, p=.006 and .038 
respectively). Stage (IIB vs IIIA/B) had no signiﬁcant inﬂuence on OS 
(HR=1.39, p=0.36) in our series.
Conclusion: Surgery is feasible after induction CRT, particularly (bi-
)lobectomy, in PS 0-1 stage IIB(Pancoast)/III NSCLC pts but pneumo-
nectomy should not be performed even if necessary (particularly, right 
pneumonectomy). Pathological response to induction chemo-RT was 
high and is a major predictive factor of OS (necrosis > 50 % or pCR). 
Survival of resected patients was encouraging. A randomized trial is 
needed to determine whether induction CRT is superior to CT alone.
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Risk of central nervous system bleeding in patients with brain 
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Background: The risk of central nervous system (CNS) bleeding in 
patients with brain metastases from NSCLC is not well known. With 
increasing use of bevacizumab, the risk of CNS hemorrhage may in-
crease. The purpose of this study was to assess the risk for CNS hemor-
rhage in NSCLC patients with one or more brain metastases enrolled in 
two large randomized trials of WBRT± Motexaﬁn gadolinium (MGd). 
Methods: In protocol 9801, 401 pts with brain metastases from any 
primary tumor were randomized to WBRT (30 Gy/10 fractions) or 
WBRT+MGd, 5 mg/kg qd x 10 days. The subgroup of 251 pts with 
NSCLC is included in this analysis. In protocol 0211, 554 pts with 
brain metastases from NSCLC were randomized to the same treat-
ments. In both studies, eligibility included a KPS ≥ 70, no liver metas-
tases, and ≤1 site of extracranial metastasis. In both studies, a primary 
endpoint was time to neurologic progression. Patients were followed 
for adverse events for one month, and for serious adverse events for 
6 months following randomization. The adverse event database was 
queried for CNS hemorrhage terms.
Results: 805 patients, with a median age of 59 years, 44.6% female, 
55.4% male, 53.3% adenocarcinoma, 19.3% NSCLC, not other-
wise speciﬁed (NOS), 13.4% squamous cell, 10.6% large cell, 0.9% 
bronchoalveolar, 19.7% single brain metastasis, 80.3% multiple 
brain metastases, 47% extracranial metastases, and 84% presenta-
tion with neurologic deﬁcits were randomized to WBRT (N=403) or 
WBRT+MGd (N=402). 12 Patients (1.5%) developed CNS bleeding: 5 
(41.7%) adenocarcinomas, 3 (25%) large cell, 2 (16.7%) each squa-
mous cell and NSCLC, NOS on average 144 days after brain metas-
tasis diagnosis (median 85 days, range 24-379 days). Patients who 
developed CNS hemorrhage presented earlier with brain metastases in 
their course of lung cancer (median of 4.1 weeks from diagnosis of the 
primary cancer to treatment of brain metastases), than those who did 
not (median 12.9 weeks). Otherwise, the characteristics of patients who 
developed CNS hemorrhage reﬂect the remainder of the population. 
The median survival of patients with CNS hemorrhage was 4.2 months 
from randomization, compared with 5.1 months for the remaining 
patients (P=0.196).
Conclusions: CNS hemorrhage is an infrequent complication of pa-
tients with brain metastases who undergo WBRT. Patients who develop 
brain metastases earlier in their disease are at greater risk.
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Background: The standard radical radiation treatment volumes used 
in Stage III non-small cell lung cancer (NSCLC) have traditionally 
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involved elective mediastinal lymph node irradiation (ELNI). With the 
advent of dose escalation and new technologies (ie. PET, 4D-CT, IMRT 
etc.), there has been a shift in treatment philosophy in the last few 
years to only including involved mediastinal nodes, which has been the 
policy at Princess Margaret Hospital, a tertiary care academic facility, 
since June 2004. We have been participating in a prospective random-
ized phase III study in Stage III NSCLC, which requires ELNI. Due 
to the difference between the institutional and study policies and the 
availability of new technologies, we reviewed the radiation treatment 
volumes of patients entered onto this study. The objective of this study 
is to determine the compliance of ELNI in this patient population.
Methods: Since September 2004 we have entered 43 patients (pts) onto 
this phase III study, which randomizes pts to PET vs no PET imaging. 
The protocol deﬁnes target volumes to include the primary tumor, ipsi-
lateral hilar lymph nodes and atleast the ipsilateral mediastinal lymph 
nodes up to the level of the clavicle and the subcarinal lymph nodes to 
atleast 3 cm below the carina regardless of the site of the primary tu-
mor. Our departmental policy deﬁnes target volumes that only include 
known mediastinal disease. We analyzed all 43 cases by reviewing 
the DRR’s (digitally reconstructed radiographs) and the plans in the 
Pinnacle radiotherapy planning system for compliance to the protocol 
target volumes.
Results: Twenty-two pts were randomized to the PET arm of the study 
and of these, 15 pts received radical radiation treatment (with concur-
rent chemotherapy). Two of the 15 received pre-operative doses of 
45Gy as part of trimodality treatment (chemotherapy, radiation and 
surgical resection), while the remaining 13 received radical doses with 
a median of 65Gy (3 pts IMRT, 10 pts 3-D conformal). Of the 21 pts 
randomized to the non-PET arm, 18 received radical radiation treat-
ment (3 pts - pre-op 45Gy, 15 pts - median 65Gy, 4 pts IMRT, 11 pts 
3-D conformal). Only one patient in each arm did not have their EMLN 
covered as per protocol. Both pts had IIIA disease involving the left 
lower lobe but did not have the upper mediastinal lymph nodes covered 
in the target volume. 
Conclusions: In this study, despite the difference in policy to include 
only known mediastinal lymph nodes and the availability of new tech-
nologies that tend to help support this shift in policy, we were able to 
for the most part adhere to protocol guidelines, which includes ELNI. 
The reasons for compliance to the protocol are multifactorial: a signiﬁ-
cant proportion of the pts in this study population had such extensive 
disease that resulted in large target volumes which inadvertently met 
the protocol guidelines; weekly review rounds to help ensure protocol 
compliance; and meticulous planning on the part of the treating Radia-
tion Oncologist.
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Background: The Gross Tumor Volume (GTV) is an important prog-
nostic factor in NSCLC radiotherapy. CT is the imaging standard for 
target delineation however functional imaging with (FDG) PET is now 
widely available. Integrating PET into CT-guided GTV delineation of-
ten changes the target volume and may reduce inter-observer variation 
however the appropriateness of these changes has not been established. 
And while PET currently shows promise in identifying the presence 
and general location of disease it is unproven as a tool for accurate, pre-
cise radiation targeting. At the present time the spatial resolution and 
image quality of PET are limited, the tumor edge location is unknown 
and it is currently unclear how best to view PET images so that they 
reﬂect actual geometry. Further work is needed to validate co-registered 
PET-CT as a tool for radiation targeting in NSCLC in order to maxi-
mise the probability of eradicating tumor. 
Hypothesis: Radiology-pathology correlation studies will help to 
clarify the relationship between pathological tumor (gold-standard), 
PET and CT dimensions in NSCLC. This will increase understanding 
of how to delineate the GTV using combined PET-CT and improve the 
accuracy of radiation targeting and the therapeutic ratio. This abstract 
reports pilot data on the difference between pathology, PET and CT 
dimensions from 6 patients enrolled in an ongoing study. 
Methods: The 3 greatest naked eye gross pathology, pre-operative PET 
(L22000/W2000, cursor placed at 50% of maximum visual intensity) 
and pre-operative CT (Level/Window 1500/-600) dimensions were 
recorded for each of 6 resected NSCLC tumors.
Results: Normalizing the pathology measurements to 100%, the range 
and median difference between these and the PET-CT measurements 
were as follows (n=18): PET range 78-214% of pathology, median 
115%; CT range 69-171%, median 108%. The Pearson correlation co-
efﬁcient between PET and pathology was 0.96, CT and pathology 0.97, 
and CT and PET 0.98 (n=18, p<0.05 for all).
Conclusion: Acknowledging the small sample size, this hypothesis-
generating pilot data suggests that when using the image settings and 
segmentation described, statistically signiﬁcant correlation exists 
between gross pathology, PET and CT tumor size in NSCLC. How-
ever this can obscure large absolute differences that may be clinically 
relevant when delineating individual GTV targets. In this dataset both 
PET and CT tended to overestimate macroscopic pathological tumor 
size as measured on fresh, non-inﬂated tissue. PET size was on average 
larger than CT perhaps reﬂecting the greater inﬂuence of tumor motion. 
Further studies are needed to conﬁrm and characterize these ﬁndings. 
Ideally these require correlation techniques with the ability to identify 
microscopic tumor extension (not detected here), a range of PET-CT 
image settings and segmentation protocols, 4-D CT imaging and mul-
tiple observers. This data provides an impetus for ongoing collaborative 
efforts to develop novel whole mount digital histopathology and 3-D 
image reconstruction methods with which to co-register and compare 
imaging, pathology and radiation treatment volumes. Any uncertainty 
in the use of PET and CT for NSCLC GTV targeting is likely to be-
come increasingly important as treatment margins are reduced and the 
use of intensity modulation and image guidance increases.
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Purpose: To report on the beneﬁt of daily administration of subcutane-
ous amifostine to limit toxicity during dose-escalated radiotherapy (RT) 
